Biologics Transition 'Dead Zone' Could Be Eliminated Under US Senate Bill

 
• By Derrick Gingery
United States Capitol Building in Washington DC USA
Stakeholder comments on the Senate drug pricing discussion draft are due to the Health, Education, Labor and Pensions Committee by 5 June. • Source: Shutterstock

More from Biosimilars

More from Biosimilars & Generics